FNP-223
Sponsors
Ferrer Internacional S.A.
Conditions
Progressive Supranuclear PalsyProgressive supranuclear palsy (PSP)
Phase 2
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Active, not recruitingNCT06355531
Start: 2024-07-23End: 2026-11-30Updated: 2025-10-15
A randomized, double-blind, placebo-controlled, Phase 2 study to assess the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) to slow the disease progression of progressive supranuclear palsy (PSP) PROSPER
Active, not recruitingCTIS2023-510366-28-00
Start: 2024-09-25Target: 183Updated: 2025-12-16